节点文献

普伐他汀联合非诺贝特治疗混合型高血脂症

The effect of pravastatin combined with fenofibrate in treatment of mixed hyperlipidemia

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 杨专青雷华孙少平阮威杰

【Author】 YANG Zhuanqing1 LEI Hua2 SUN Shaoping1 RUAN Weijie1 1.Department of Vasculocardiology,Dongguan City Tangxia Hospital,Guangdong Province,Dongguan 523721,China;2.Department of Pharmacy,Dongguan City Tangxia Hospital,Guangdong Province,Dongguan 523721,China

【机构】 广东省东莞市塘厦医院心血管内科广东省东莞市塘厦医院药剂科

【摘要】 目的探讨联用普伐他汀和非诺贝特治疗混合型高血脂症的临床疗效。方法按照随机数字法将211例混合型高血脂症患者随机分为联合组、普伐他汀组和非诺贝特组,其中联合组采用低剂量的普伐他汀与非诺贝特联合治疗,普伐他汀组和非诺贝特组分别采用普伐他汀和非诺贝特单独治疗,比较三组的临床血脂指标、疗效和不良反应。结果联合组的总有效率明显高于普伐他汀组和非诺贝特组(P<0.05)。三组的不良反应无明显差异(P>0.05)。结论联用普伐他汀和非诺贝特治疗混合型高血脂症具有良好的临床疗效,且不良反应少,值得临床推广使用。

【Abstract】 Objective To investigate the clinical effect of pravastatin and fenofibrate in treatment of mixed hyperlipidemia.Methods All of 211 cases of mixed hyperlipidemia patients were randomly divided into combined group,pravastatin group and fenofibrate group,in which low-dose combination group fenofibrate combination therapy with pravastatin,pravastatin group and fenofibrate group were used to separate treatment of pravastatin and fenofibrate.Clinical lipid levels,efficacy and adverse reactions compared in three groups.Results The total effective rate of combined group was significantly higher than pravastatin group and fenofibrate group(P < 0.05).Three groups had no significant difference in adverse events(P > 0.05).Conclusion Pravastatin combined with fenofibrate in treatment of mixed hyperlipidemia has a good clinical efficacy,fewer adverse reactions.So it is worthy of clinical use.

  • 【文献出处】 中国现代医生 ,China Modern Doctor , 编辑部邮箱 ,2012年06期
  • 【分类号】R589.2
  • 【被引频次】9
  • 【下载频次】69
节点文献中: 

本文链接的文献网络图示:

本文的引文网络